Efficacy and Safety of Oral Methazolamide in Patients With Type 2 Diabetes: A 24-Week, Placebo-Controlled, Double-Blind Study

被引:12
|
作者
Simpson, Richard W. [1 ]
Nicholson, Geoffrey C. [2 ]
Proietto, Joseph [3 ]
Sarah, Alana [4 ]
Sanders, Kerrie M. [2 ]
Phillips, Gabrielle [1 ]
Chambers, Jo [4 ]
MacGinley, Rob [5 ]
Orford, Neil [6 ]
Walder, Ken [5 ]
Krippner, Guy [7 ]
Skoff, Kathy [7 ]
Wacher, Vincent J. [7 ]
机构
[1] Box Hill Hosp, Box Hill, Vic, Australia
[2] Univ Melbourne, Geelong Hosp, Dept Clin & Biomed Sci, Melbourne, Vic, Australia
[3] Univ Melbourne, Heidelberg Repatriat Hosp, Melbourne, Vic, Australia
[4] Barwon Hlth, Dept Med, Clin Trial Unit, Geelong, Vic, Australia
[5] Deakin Univ, Geelong, Vic 3217, Australia
[6] Monash Univ, Dept Epidemiol & Prevent Med, Barwon Hlth Australian & New Zealand Intens Care, Melbourne, Vic 3004, Australia
[7] Verva Pharmaceut Ltd, Southbank, Vic, Australia
关键词
FATTY LIVER-DISEASE;
D O I
10.2337/dc14-1038
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To evaluate the safety and efficacy of methazolamide as a potential therapy for type 2 diabetes. RESEARCH DESIGN AND METHODS This double-blind, placebo-controlled study randomized 76 patients to oral methazolamide (40 mg b.i.d.) or placebo for 24 weeks. The primary efficacy end point for methazolamide treatment was a placebo-corrected reduction in HbA(1c) from baseline after 24 weeks (Delta HbA(1c)). RESULTS Mean +/- SD baseline HbA(1c) was 7.1 +/- 0.7% (54 +/- 5 mmol/mol; n = 37) and 7.4 +/- 0.6% (57 +/- 5 mmol/mol; n 5 39) in the methazolamide and placebo groups, respectively. Methazolamide treatment was associated with a Delta HbA(1c) of -0.39% (95% CI -0.82, 0.04; P < 0.05) (-4.3 mmol/mol [-9.0, 0.4]), an increase in the proportion of patients achieving HbA(1c) <= 6.5% (48 mmol/mol) from 8 to 33%, a rapid reduction in alanine aminotransferase (similar to 10 units/L), and weight loss (2%) in metformin-cotreated patients. CONCLUSIONS Methazolamide is the archetype for a new intervention in type 2 diabetes with clinical benefits beyond glucose control.
引用
收藏
页码:3121 / 3123
页数:3
相关论文
共 50 条
  • [1] Efficacy and safety of canagliflozin rnonotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study
    Inagaki, Nobuya
    Kondo, Kazuoki
    Yoshinari, Toru
    Takahashi, Nahoko
    Susuta, Yutaka
    Kuki, Hideki
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (11) : 1501 - 1515
  • [2] Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
    Haering, Hans-Ulrich
    Merker, Ludwig
    Seewaldt-Becker, Elke
    Weimer, Marc
    Meinicke, Thomas
    Broedl, Uli C.
    Woerle, Hans J.
    [J]. DIABETES CARE, 2014, 37 (06) : 1650 - 1659
  • [3] Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes
    Rubin, Cindy J.
    Viraswami-Appanna, Kalyanee
    Fiedorek, Fred T.
    [J]. DIABETES & VASCULAR DISEASE RESEARCH, 2009, 6 (03): : 205 - 215
  • [4] Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial
    Kadowaki, Takashi
    Inagaki, Nobuya
    Kondo, Kazuoki
    Nishimura, Kenichi
    Kaneko, Genki
    Maruyama, Nobuko
    Nakanishi, Nobuhiro
    Iijima, Hiroaki
    Watanabe, Yumi
    Gouda, Maki
    [J]. DIABETES OBESITY & METABOLISM, 2017, 19 (06): : 874 - 882
  • [5] Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study
    Inagaki, N.
    Kondo, K.
    Yoshinari, T.
    Maruyama, N.
    Susuta, Y.
    Kuki, H.
    [J]. DIABETES OBESITY & METABOLISM, 2013, 15 (12): : 1136 - 1145
  • [6] Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial
    Dubourg, Julie
    Ueki, Kohjiro
    Grouin, Jean-Marie
    Fouqueray, Pascale
    [J]. DIABETES OBESITY & METABOLISM, 2021, 23 (03): : 800 - 810
  • [7] Vildagliptin in drug-naive patients with type 2 diabetes: A 24-week, double-blind, randomized, placebo-controlled, multiple-dose study
    Dejager, S.
    Razac, S.
    Foley, J. E.
    Schweizer, A.
    [J]. HORMONE AND METABOLIC RESEARCH, 2007, 39 (03) : 218 - 223
  • [8] Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: A 24-week, randomized, double-blind, placebo-controlled trial
    Halvorsen, Yuan-Di
    Conery, Annie L.
    Lock, John Paul
    Zhou, Wenjiong
    Freeman, Mason W.
    [J]. DIABETES OBESITY & METABOLISM, 2023, 25 (10): : 2954 - 2962
  • [9] A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
    Rogers, SL
    Farlow, MR
    Doody, RS
    Mohs, R
    Friedhoff, LT
    Albala, B
    Baumel, B
    Booker, G
    Dexter, J
    Farmer, M
    Feighner, JP
    Ferris, S
    Gordon, B
    Gorman, DG
    Hanna, G
    Harrell, LE
    Hubbard, R
    Kennedy, J
    McCarthy, J
    Scharre, DW
    Schaerf, F
    Schneider, L
    Seltzer, B
    Siegal, A
    Stark, SR
    Strauss, A
    Walshe, TM
    [J]. NEUROLOGY, 1998, 50 (01) : 136 - 145
  • [10] Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes A 24-week, randomized, double-blind, placebo-controlled trial
    Haering, Hans-Ulrich
    Merker, Ludwig
    Seewaldt-Becker, Elke
    Weimer, Marc
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES CARE, 2013, 36 (11) : 3396 - 3404